recombinant human col1a1 protein Search Results


94
R&D Systems pro collagen i alpha 1 pro cola1
Pro Collagen I Alpha 1 Pro Cola1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+col1a1+protein/pmc11912118-190-5-25?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
pro collagen i alpha 1 pro cola1 - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
R&D Systems recombinant human pro collagen

Recombinant Human Pro Collagen, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+col1a1+protein/pmc06349404-25-4-10?v=R%26D+Systems
Average 94 stars, based on 1 article reviews
recombinant human pro collagen - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
OriGene human col1a1
( A ) Volcano plot of differential autoantibody reactivity (PhIP-Seq peptides) between ARF cases and healthy controls. Significant peptides (using DESeq2, adjusted P < 0.05) colored by average binding magnitude, nonsignificant by sample density. Number of peptides significantly elevated in ARF cases compares with healthy controls is indicated; 118 peptides mapping to 81 proteins. Dashed lines indicate thresholds for significance and no change; enriched targets PPP1R12B and <t>COL1A1</t> labeled. Total magnitude indicated by red scale; ARF significantly elevated magnitude compared with healthy controls by 1-sided Wilcoxon’s test. P = 0.018, r = 0.35. ( B ) GO pathway enrichment for ARF-associated autoantigens ( P < 0.01, 81 proteins represented by 118 peptides in A ). Dot size reflects protein count per pathway; fill color indicates enrichment strength. Outlines denote GO categories: Cellular Component (blue), Biological Process (green). Highlighted pathways include Sarcomere and Heart Morphogenesis. Full pathway analysis results with enrichment metrics for all GO terms are provided in . ( C ) Heart muscle expression of ARF-enriched targets (Human Protein Atlas). Upper panel: RNA expression ordered from low to high; tile borders indicate multiple (green) or single (gray) peptide hits. Lower panel: Protein expression by immunohistochemistry; tile borders indicate staining reliability (enhanced, red; supported, orange; approved, pink; uncertain, gray). Red arrows highlight PPP1R12B and COL1A1. ( D ) Subcellular localization and secretion prediction (Human Protein Atlas). Upper panel: Localization across cellular compartments (purple = presence); borders show reliability. Lower panel: Secreted proteins prediction (violet = predicted secreted). Main locations shaded if proteins predicted secreted as main location. PPP1R12B and COL1A1 indicated by red arrows.
Human Col1a1, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+col1a1+protein/pmc12890473-188-7-12?v=OriGene
Average 93 stars, based on 1 article reviews
human col1a1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

N/A
This gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant
  Buy from Supplier

N/A
Protein Function:Type I collagen is the most abundant structural protein of connective tissues such as skin, bone and tendon. It is synthesized as a procollagen molecule which is characterized by a 300 nm triple helical
  Buy from Supplier

N/A
This gene encodes the pro-alpha1 chains of type I collagen whose triple helix comprises two alpha1 chains and one alpha2 chain. Type I is a fibril-forming collagen found in most connective tissues and is abundant
  Buy from Supplier

N/A
The Recombinant Human Pro Collagen I alpha 1 COL1A1 Protein from R D Systems is derived from CHO The Recombinant Human Pro Collagen I alpha 1 COL1A1 Protein has been validated for the following applications
  Buy from Supplier

Image Search Results


Journal: eLife

Article Title: Integrin alpha11 is an Osteolectin receptor and is required for the maintenance of adult skeletal bone mass

doi: 10.7554/eLife.42274

Figure Lengend Snippet:

Article Snippet: Peptide, recombinant protein , recombinant human pro-Collagen I α1 , R and D Systems , 6220 CL , .

Techniques: Recombinant, Diagnostic Assay, Cell Culture, Protease Inhibitor, Western Blot, Reverse Transcription, Enzyme-linked Immunosorbent Assay, Fractionation

( A ) Volcano plot of differential autoantibody reactivity (PhIP-Seq peptides) between ARF cases and healthy controls. Significant peptides (using DESeq2, adjusted P < 0.05) colored by average binding magnitude, nonsignificant by sample density. Number of peptides significantly elevated in ARF cases compares with healthy controls is indicated; 118 peptides mapping to 81 proteins. Dashed lines indicate thresholds for significance and no change; enriched targets PPP1R12B and COL1A1 labeled. Total magnitude indicated by red scale; ARF significantly elevated magnitude compared with healthy controls by 1-sided Wilcoxon’s test. P = 0.018, r = 0.35. ( B ) GO pathway enrichment for ARF-associated autoantigens ( P < 0.01, 81 proteins represented by 118 peptides in A ). Dot size reflects protein count per pathway; fill color indicates enrichment strength. Outlines denote GO categories: Cellular Component (blue), Biological Process (green). Highlighted pathways include Sarcomere and Heart Morphogenesis. Full pathway analysis results with enrichment metrics for all GO terms are provided in . ( C ) Heart muscle expression of ARF-enriched targets (Human Protein Atlas). Upper panel: RNA expression ordered from low to high; tile borders indicate multiple (green) or single (gray) peptide hits. Lower panel: Protein expression by immunohistochemistry; tile borders indicate staining reliability (enhanced, red; supported, orange; approved, pink; uncertain, gray). Red arrows highlight PPP1R12B and COL1A1. ( D ) Subcellular localization and secretion prediction (Human Protein Atlas). Upper panel: Localization across cellular compartments (purple = presence); borders show reliability. Lower panel: Secreted proteins prediction (violet = predicted secreted). Main locations shaded if proteins predicted secreted as main location. PPP1R12B and COL1A1 indicated by red arrows.

Journal: JCI Insight

Article Title: PhIP-Seq uncovers marked heterogeneity in acute rheumatic fever autoantibodies

doi: 10.1172/jci.insight.196619

Figure Lengend Snippet: ( A ) Volcano plot of differential autoantibody reactivity (PhIP-Seq peptides) between ARF cases and healthy controls. Significant peptides (using DESeq2, adjusted P < 0.05) colored by average binding magnitude, nonsignificant by sample density. Number of peptides significantly elevated in ARF cases compares with healthy controls is indicated; 118 peptides mapping to 81 proteins. Dashed lines indicate thresholds for significance and no change; enriched targets PPP1R12B and COL1A1 labeled. Total magnitude indicated by red scale; ARF significantly elevated magnitude compared with healthy controls by 1-sided Wilcoxon’s test. P = 0.018, r = 0.35. ( B ) GO pathway enrichment for ARF-associated autoantigens ( P < 0.01, 81 proteins represented by 118 peptides in A ). Dot size reflects protein count per pathway; fill color indicates enrichment strength. Outlines denote GO categories: Cellular Component (blue), Biological Process (green). Highlighted pathways include Sarcomere and Heart Morphogenesis. Full pathway analysis results with enrichment metrics for all GO terms are provided in . ( C ) Heart muscle expression of ARF-enriched targets (Human Protein Atlas). Upper panel: RNA expression ordered from low to high; tile borders indicate multiple (green) or single (gray) peptide hits. Lower panel: Protein expression by immunohistochemistry; tile borders indicate staining reliability (enhanced, red; supported, orange; approved, pink; uncertain, gray). Red arrows highlight PPP1R12B and COL1A1. ( D ) Subcellular localization and secretion prediction (Human Protein Atlas). Upper panel: Localization across cellular compartments (purple = presence); borders show reliability. Lower panel: Secreted proteins prediction (violet = predicted secreted). Main locations shaded if proteins predicted secreted as main location. PPP1R12B and COL1A1 indicated by red arrows.

Article Snippet: Recombinant antigens were either obtained commercially — human COL1A1 ( NM_000088 , Origene) and PPP1R12B ( NM_032104 , Origene) — or produced recombinantly using Expi293 cells as the expression host and purified using standard nickel affinity and size exclusion chromatography (CD226; NM_006566 , Callaghan Innovation).

Techniques: Binding Assay, Labeling, Immunopeptidomics, Expressing, RNA Expression, Immunohistochemistry, Staining

( A ) Top: Schematic of PhIP-Seq peptide tiling for PPP1R12B protein; significant peptides (green) cluster at C-terminus. Middle: Heatmap of normalized, bead-corrected enrichment across PPP1R12B for ARF cases (purple) and controls (gold), clustered by donor profiles. Bottom: Mean enrichment for ARF and controls. ( B ) Individual peptide enrichment for PPP1R12B peptides in ARF (purple) versus controls (gold); significantly enriched peptides (17A, 18B, 19A) highlighted green with P values from 2 analysis shown in black text above. ( C ) Correlation of enriched PPP1R12B peptides in ARF. Upper panels: Pearson’s correlation coefficient ( r ) with P values from the regression show in red text. Lower panels: Scatterplots with regression lines and R 2 values. ( D ) Enrichment of COL1A1 peptides in ARF (purple) and controls (gold). ( E ) Correlation analysis between COL1A1 peptides in ARF. Upper panel: Pearson’s correlation coefficient ( r ) with P values from the regression shown in red text. Lower panels: scatterplots with regression lines and R 2 values. Box-and-whisker plots show median (line in box), interquartile range (IQR, box bounds), and 1.5 × IQR (whiskers).

Journal: JCI Insight

Article Title: PhIP-Seq uncovers marked heterogeneity in acute rheumatic fever autoantibodies

doi: 10.1172/jci.insight.196619

Figure Lengend Snippet: ( A ) Top: Schematic of PhIP-Seq peptide tiling for PPP1R12B protein; significant peptides (green) cluster at C-terminus. Middle: Heatmap of normalized, bead-corrected enrichment across PPP1R12B for ARF cases (purple) and controls (gold), clustered by donor profiles. Bottom: Mean enrichment for ARF and controls. ( B ) Individual peptide enrichment for PPP1R12B peptides in ARF (purple) versus controls (gold); significantly enriched peptides (17A, 18B, 19A) highlighted green with P values from 2 analysis shown in black text above. ( C ) Correlation of enriched PPP1R12B peptides in ARF. Upper panels: Pearson’s correlation coefficient ( r ) with P values from the regression show in red text. Lower panels: Scatterplots with regression lines and R 2 values. ( D ) Enrichment of COL1A1 peptides in ARF (purple) and controls (gold). ( E ) Correlation analysis between COL1A1 peptides in ARF. Upper panel: Pearson’s correlation coefficient ( r ) with P values from the regression shown in red text. Lower panels: scatterplots with regression lines and R 2 values. Box-and-whisker plots show median (line in box), interquartile range (IQR, box bounds), and 1.5 × IQR (whiskers).

Article Snippet: Recombinant antigens were either obtained commercially — human COL1A1 ( NM_000088 , Origene) and PPP1R12B ( NM_032104 , Origene) — or produced recombinantly using Expi293 cells as the expression host and purified using standard nickel affinity and size exclusion chromatography (CD226; NM_006566 , Callaghan Innovation).

Techniques: Whisker Assay

( A ) Schematic representation of the PPP1R12B PhIP-Seq peptide tiling and design of synthetic peptides used for validation. The 3 overlapping PhIP-Seq peptides significantly enriched in ARF (17A, 18B, 19A) localize to a contiguous region of the protein. Two nonoverlapping 45-mer peptides (Pep-1 and Pep-2) were synthesized spanning this region, with Pep-2 fully contained within the recombinant protein used for whole-protein ELISA. Created with Biorender. ( B ) Whole-protein ELISA responses to PPP1R12B, COL1A1, and CD226 in the discovery cohort (ARF vs. healthy). Violin plots with points; white circle symbols show the median, with IQR as error bars. Horizontal dashed lined indicate the reference threshold of 2 times the median of healthy controls. ( C ) Median absorbance in PPP1R12B peptide ELISAs in the discovery cohort; dashed lines indicate the reference threshold of 2 times the median of healthy controls. Wilcoxon’s P values (ARF vs. healthy) are shown per peptide. ( D ) Spearman’s correlation of PhIP-Seq normalized enrichment values for peptide 18B with ELISA absorbance values for PPP1R12B whole protein and Pep-2 with fitted linear regression lines (black) and Spearman’s correlation coefficient with significance shown in black text. ( E ) Discovery ROC for Pep-2 on the absorbance scale (ARF vs. healthy). The prespecified operating cutoff is marked in red with dotted guides. AUC and 95% CI are shown on the plot. ( F ) Independent validation cohort (ARF, healthy, and Strep A–positive pharyngitis controls): distribution of Pep-2 absorbance with the prespecified discovery cutoff (red dashed line). Wilcoxon’s P values are shown throughout in black text.

Journal: JCI Insight

Article Title: PhIP-Seq uncovers marked heterogeneity in acute rheumatic fever autoantibodies

doi: 10.1172/jci.insight.196619

Figure Lengend Snippet: ( A ) Schematic representation of the PPP1R12B PhIP-Seq peptide tiling and design of synthetic peptides used for validation. The 3 overlapping PhIP-Seq peptides significantly enriched in ARF (17A, 18B, 19A) localize to a contiguous region of the protein. Two nonoverlapping 45-mer peptides (Pep-1 and Pep-2) were synthesized spanning this region, with Pep-2 fully contained within the recombinant protein used for whole-protein ELISA. Created with Biorender. ( B ) Whole-protein ELISA responses to PPP1R12B, COL1A1, and CD226 in the discovery cohort (ARF vs. healthy). Violin plots with points; white circle symbols show the median, with IQR as error bars. Horizontal dashed lined indicate the reference threshold of 2 times the median of healthy controls. ( C ) Median absorbance in PPP1R12B peptide ELISAs in the discovery cohort; dashed lines indicate the reference threshold of 2 times the median of healthy controls. Wilcoxon’s P values (ARF vs. healthy) are shown per peptide. ( D ) Spearman’s correlation of PhIP-Seq normalized enrichment values for peptide 18B with ELISA absorbance values for PPP1R12B whole protein and Pep-2 with fitted linear regression lines (black) and Spearman’s correlation coefficient with significance shown in black text. ( E ) Discovery ROC for Pep-2 on the absorbance scale (ARF vs. healthy). The prespecified operating cutoff is marked in red with dotted guides. AUC and 95% CI are shown on the plot. ( F ) Independent validation cohort (ARF, healthy, and Strep A–positive pharyngitis controls): distribution of Pep-2 absorbance with the prespecified discovery cutoff (red dashed line). Wilcoxon’s P values are shown throughout in black text.

Article Snippet: Recombinant antigens were either obtained commercially — human COL1A1 ( NM_000088 , Origene) and PPP1R12B ( NM_032104 , Origene) — or produced recombinantly using Expi293 cells as the expression host and purified using standard nickel affinity and size exclusion chromatography (CD226; NM_006566 , Callaghan Innovation).

Techniques: Biomarker Discovery, Synthesized, Recombinant, Enzyme-linked Immunosorbent Assay